Newsroom
Stay up to date on the latest Legend news and information from Legend Biotech.
Stay up to date on the latest Legend news and information from Legend Biotech.
SOMERSET, N.J. — (BUSINESS WIRE) —June 1, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its first quarter 2022 unaudited financial results. “The year began with an exciting start as we received the company’s first-ever U.S. FDA approval for […]
Jun 01, 2022
SOMERSET, N.J.—(BUSINESS WIRE)—May 31, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it will host an investor event during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Taking place on Sunday, June 5 at 6pm Central Time, […]
May 31, 2022
CARVYKTI® is Legend Biotech’s first European Commission-approved product The approval is based on the pivotal phase 1b/2 CARTITUDE-1 study, which demonstrated an overall response rate (ORR) of 98 percent in patients with relapsed or refractory multiple myeloma following a one-time treatment with ciltacabtagene autoleucel SOMERSET, N.J.— (BUSINESS WIRE)—May 26, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend […]
May 26, 2022
U.S. FDA approval of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) SOMERSET, N.J.— (BUSINESS WIRE)—May 18, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that eight company-sponsored abstracts were accepted at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the […]
May 18, 2022
SOMERSET, N.J.— (BUSINESS WIRE)—May 9, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the promotion of Lori Macomber, CPA, to Chief Financial Officer (CFO), effective immediately. Ms. Macomber assumes the role from Dr. Ying Huang, who has been both CFO […]
May 09, 2022
Thank you for your interest in learning more about Legend Biotech.
media@legendbiotech.com
You are going to a website that Legend Biotech does not operate and to which Legend Biotech's privacy policy does not apply. Legend Biotech is not responsible for the content, format, maintenance or policies of the website you are about to visit and does not endorse or monitor any content on such website.